---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-006004"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:10:31.562249+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27

## Summary
- Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.
- Cash and investments $81.0M as of March 31, 2025; Q1 cash burn $16.9M; runway into 2026.
- BLA for PRGN-2012 (RRP) under FDA priority review; PDUFA target action date August 27, 2025.
- Pivotal study: 51% complete response, 86% reduction in surgeries; median follow-up 30 months.
- Selected EVERSANA for commercialization support; advancing launch readiness for potential 2025 launch.

## SEC filing metadata
- accession: 0000950103-25-006004
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/0000950103-25-006004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/dp228863_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-006004
- JSON: https://secwatch.observer/filing/0000950103-25-006004.json
- Plain text: https://secwatch.observer/filing/0000950103-25-006004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.